Investors may wish to note that the CEO, President & Director of Sagimet Biosciences Inc., David Happel, recently netted US$65k from selling stock, receiving an average price of US$5.36. On the bright side, that's just a small sale and only reduced their holding by 4.2%.

The Last 12 Months Of Insider Transactions At Sagimet Biosciences

Notably, that recent sale by CEO, President & Director David Happel was not the only time they sold Sagimet Biosciences shares this year. They previously made an even bigger sale of -US$598k worth of shares at a price of US$9.13 per share. While we don't usually like to see insider selling, it's more concerning if the sales take place at a lower price. It's of some comfort that this sale was conducted at a price well above the current share price, which is US$5.06. So it may not tell us anything about how insiders feel about the current share price.

In the last year Sagimet Biosciences insiders didn't buy any company stock. You can see a visual depiction of insider transactions (by companies and individuals) over the last 12 months, below. If you click on the chart, you can see all the individual transactions, including the share price, individual, and the date!

If you like to buy stocks that insiders are buying, rather than selling, then you might just love this free list of companies. (Hint: Most of them are flying under the radar).

Does Sagimet Biosciences Boast High Insider Ownership?

I like to look at how many shares insiders own in a company, to help inform my view of how aligned they are with insiders. I reckon it's a good sign if insiders own a significant number of shares in the company. Our data suggests Sagimet Biosciences insiders own 1.6% of the company, worth about US$2.6m. We consider this fairly low insider ownership.

What Might The Insider Transactions At Sagimet Biosciences Tell Us?

Insiders sold Sagimet Biosciences shares recently, but they didn't buy any. And there weren't any purchases to give us comfort, over the last year. Insiders own relatively few shares in the company, and when you consider the sales, we're not particularly excited about the stock. So we'd only buy after very careful consideration. While it's good to be aware of what's going on with the insider's ownership and transactions, we make sure to also consider what risks are facing a stock before making any investment decision. At Simply Wall St, we've found that Sagimet Biosciences has 4 warning signs (2 are a bit concerning!) that deserve your attention before going any further with your analysis.

Of course Sagimet Biosciences may not be the best stock to buy. So you may wish to see this free collection of high quality companies.

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.